06 July 2020
Three Russian prototypes of the vaccine against COVID-19 have demonstrated their efficacy in a series of tests, Rinat Maksiutov, Director General of the State Research Center for Virology and Biotechnology “Vector”, said in an interview to RIA Novosti.
At present, three prototypes of the vaccine against covid-19 have been successfully tested and proved capable of inducing immune response. These are the most advanced drugs in terms of efficacy,” he said.
At present, a total of 100 researchers from Vector are working on vaccines, Maksiutov pointed out. He added that the most important task was to design a vaccine offering the best possible protection against the disease. “The biggest challenge is to create a vaccine that is both potent and safe,” Vector’s Director-General said.
If the vaccine performs well on the safety and efficacy tests, Vector will launch clinical trials on July 15. The trials will be attended by 300 volunteers, Maksiutov said.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024